SMO ClinPlus Co. Ltd. Asset Resilience Ratio
SMO ClinPlus Co. Ltd. asset resilience ratio. SMO ClinPlus Co. Ltd. (301257) has an Asset Resilience Ratio of 15.78% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of SMO ClinPlus Co. Ltd. to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SMO ClinPlus Co. Ltd. (2022–2025)
Asset resilience ratio of SMO ClinPlus Co. Ltd. from 2022 to 2025. This chart shows how SMO ClinPlus Co. Ltd.'s Asset Resilience Ratio has changed over time. Read 301257 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SMO ClinPlus Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SMO ClinPlus Co. Ltd. (301257) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥240.57 Million | 15.78% |
| Total Liquid Assets | CN¥240.57 Million | 15.78% |
Asset Resilience Insights
- Good Liquidity Position: SMO ClinPlus Co. Ltd. maintains a healthy 15.78% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
SMO ClinPlus Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare SMO ClinPlus Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
SMO ClinPlus Co. Ltd. Asset Resilience Ratio by Year (2022–2025)
SMO ClinPlus Co. Ltd. asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for SMO ClinPlus Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.74% | CN¥150.31 Million ≈ $21.99 Million |
CN¥1.54 Billion ≈ $225.92 Million |
-18.28pp |
| 2024-12-31 | 28.02% | CN¥400.58 Million ≈ $58.62 Million |
CN¥1.43 Billion ≈ $209.20 Million |
-2.79pp |
| 2023-12-31 | 30.81% | CN¥421.14 Million ≈ $61.63 Million |
CN¥1.37 Billion ≈ $200.01 Million |
+19.06pp |
| 2022-12-31 | 11.75% | CN¥136.38 Million ≈ $19.96 Million |
CN¥1.16 Billion ≈ $169.85 Million |
-- |
About SMO ClinPlus Co. Ltd.
SMO ClinPlus CO.,LTD. provides site management services in research and development in pharmaceuticals, medical devices, and health-related products in China. It offers clinical trial site management organization services to pharmaceuticals, medical devices, CRO companies, etc. The company offers preliminary modeling and preparation plans, trial site initiation, on-site execution, and project man… Read more